Sign up Canada
Proactive Investors - Run By Investors For Investors

Oragenics touts new drug to fight clostridium difficile

Golden Syrian hamsters infected with clostridium difficile and treated with the drug OG716 were cured and didn't suffer a relapse
Petri dishes
Research about OG716's success was published in PLOS One, a peer-reviewed scientific journal

New research by Oragenics Inc (NYSE American: OGEN), a Tampa-based clinical-stage biotech group, has uncovered a novel type of antibiotic known as a lantibiotic for the treatment of clostridium difficile, an infection causing colitis, called OG716.

When golden Syrian hamsters infected with clostridium difficile were treated with the drug OG716, a variant of the lantibiotic Mutacin 1140, 100% survived and were cured of the disease. Also, the hamsters did not suffer a relapse of the disease after three weeks since the time they were infected.

Given its success in treating clostridium difficile, Oragenics is looking to submit an investigational new drug application for OG716 next year.

Watch: Oragenics raises US$1.8mln to develop treatment for oral mucositis

“We believe that OG716 holds the potential to be an effective treatment for C. difficile while reducing the risk of developing drug resistance,” said Dr Alan Joslyn, Oragenic’s CEO. “C. difficile infections have become an increasing health risk worldwide as new drug-resistant strains have appeared, causing an increase in mortality rates by more than 400%.”

Read: Oragenics shares surge after positive safety results in Phase 2 drug trial

Clostridium difficile is an infection causing colitis by producing toxins that damage the lining of the colon. It is considered a threat by the Centers for Disease Control and Prevention, with an incidence rate of 500,000 infections per year and a mortality rate of 29,000 deaths each year. C difficile infections are frequently acquired in hospitals, which means that a broader population is at risk of catching the disease.

The research about OG716's success was published in PLOS One, a peer-reviewed scientific journal published by the Public Library of Science as part of a paper entitled "OG716: designing a fit-for-purpose antibiotic for the treatment of Clostridium difficile infections."

Oragenics Inc shares are up 1.4% at US$1.43 in afternoon trade.

View full OGEN profile View Profile

Related Articles

1538160791_petri-dishes.jpg
September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
3d rendering of an antibody
July 24 2018
It is teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, a professor at Tufts University School of Medicine, Boston
bacteria
September 25 2018
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use